|
1
|
Elkis H and Buckley PF:
Treatment-resistant schizophrenia. Psychiatr Clin North Am.
39:239–265. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Demjaha A, Lappin JM, Stahl D, Patel MX,
MacCabe JH, Howes OD, Heslin M, Reininghaus UA, Donoghue K, Lomas
B, et al: Antipsychotic treatment resistance in first-episode
psychosis: Prevalence, subtypes and predictors. Psychol Med.
47:1981–1989. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lehman AF, Lieberman JA, Dixon LB,
McGlashan TH, Miller AL, Perkins DO and Kreyenbuhl J: American
Psychiatric Association; Steering Committee on Practice Guidelines.
American psychiatric association and steering committee on practice
guidelines. practice guideline for the treatment of patients with
schizophrenia, second edition. Am J Psychiatry. 161 (Suppl
2):S1–S56. 2004.PubMed/NCBI
|
|
4
|
Taylor DM: Clozapine for
treatment-resistant schizophrenia: Still the gold standard? CNS
Drugs. 31:177–180. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cohen D: Prescribers fear as a major
side-effect of clozapine. Acta Psychiatr Scand. 130:154–159.
2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Verdoux H, Bittner RA, Hasan A, Qubad M,
Wagner E, Lepetit A, Romero MA, Bachmann C, Beex-Oosterhuis M,
Bogers J, et al: The time has come for revising the rules of
clozapine blood monitoring in Europe. A joint expert statement from
the European clozapine task force. Eur Psychiatry.
68(e17)2025.PubMed/NCBI View Article : Google Scholar
|
|
7
|
De Leon J, Armstrong SC and Cozza KL: The
dosing of atypical antipsychotics. Psychosomatics. 46:262–73.
2005.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mach A, Wnorowska A, Siwek M, Wojnar M and
Radziwoń-Zaleska M: Clinical and pharmacological factors
influencing serum clozapine and norclozapine levels. Front
Pharmacol. 15(1356813)2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tralongo F, Konecki C, Feliu C, Kaladjian
A and Djerada Z: Association between clozapine plasma
concentrations and treatment response: A systematic review,
meta-analysis and individual participant data meta-analysis. Clin
Pharmacokinet. 62:807–818. 2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Nomura N, Kitagawa K, So R, Misawa F,
Kodama M, Takeuchi H, Bies R, Straubinger T..Banker C, Mizuno Y, et
al: Comprehensive assessment of exposure to clozapine in
association with side effects among patients with
treatment-resistant schizophrenia: A population pharmacokinetic
study. Ther Adv Psychopharmacol.
11(20451253211016189)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
de Haas HJ, Cohen D, de Koning MB, van
Weringh G, Petrovic V, de Haan L, Touw DJ and Ignjatovic Ristic D:
Clozapine levels and outcomes in Serbian patients with
treatment-resistant psychotic disorders previously treated without
measuring clozapine levels (CLOSER). Psychiatry Res.
339(116070)2024.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hynes C, Keating D, McWilliams S, Madigan
K, Kinsella A, Maidment I, Feetam C, Drake RJ, Haddad PM, Gaughran
F, et al: Glasgow antipsychotic sideeffects scale for
clozapine-development and validation of a clozapine-specific
side-effects scale. Schizophr Res. 168:505–513. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Seppälä N, Leinonen E, Viikki M, Solismaa
A, Nuolivirta T and Kampman O: Factors associated with subjective
side-effects during clozapine treatment. Nord J Psychiatry.
69:161–166. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yusufi B, Mukherjee S, Flanagan R, Paton
C, Dunn G, Page E and Barnes TR: Prevalence and nature of
side-effects during clozapine maintenance treatment and the
relationship with clozapine dose and plasma concentration. Int Clin
Psychopharmacol. 22:238–243. 2007.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Naber D, Moritz S, Lambert M, Pajonk GF,
Holzbach R, Mass R and Andresen B: Improvement of schizophrenic
patients' subjective well-being under atypical antipsychotic drugs.
Schizophr Res. 30: 50:79–88. 2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gürcan G, Hun Şenol Ş, Anıl Yağcıoğlu AE,
Karahan S and Ertuğrul A: Common side effects and metabolic
syndrome due to clozapine: Relationship with the clinical variables
and disability. Turk Psikiyatri Derg. 32:87–99. 2021.PubMed/NCBI View
Article : Google Scholar : (In English,
Turkish).
|
|
17
|
Charlson FJ, Ferrari AJ, Santomauro DF,
Diminic S, Stockings E, Scott JG, McGrath JJ and Whiteford HA:
Global epidemiology and burden of schizophrenia: Findings from the
global burden of disease study 2016. Schizophr Bull. 44:1195–1203.
2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Taylor D, Paton C and Kapur S: Maudsley
Prescribing Guidelines in Psychiatry. 12th Edition.
Wiley-Blackwell, Oxford, 165-85, 2015.
|
|
19
|
Bleakley S and Taylor D: The Clozapine
Handbook. 1st Edition. Lloyd-Reinhold Communications LLP,
Warwickshire, pp36-119, 2013.
|
|
20
|
De Berardis D, Rapini G, Olivieri L, Di
Nicola D, Tomasetti C, Valchera A, Fornaro M, Di Fabio F, Perna G,
Di Nicola M, et al: Safety of antipsychotics for the treatment of
schizophrenia: A focus on the adverse effects of clozapine. Ther
Adv Drug Saf. 9:237–256. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ignjatović Ristić D, Cohen D, Obradović A,
Nikić-Đuričić K, Drašković M and Hinić D: The Glasgow antipsychotic
side-effects scale for clozapine in inpatients and outpatients with
schizophrenia or schizoaffective disorder. Nord J Psychiatry.
72:124–129. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
World Health Organization (WHO). World
Report on Disability 2011. https://www.who.int/disabilities/world_report/2011/report.
|
|
23
|
Zipursky RB, Reilly TJ and Murray RM: The
myth of schizophrenia as a progressive brain disease. Schizophr
Bull. 39:1363–1372. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Cheniaux E, Landeira-Fernandez J, Lessa
Telles L, Lessa JL, Dias A, Duncan T and Versiani M: Does
schizoaffective disorder really exist? A systematic review of the
studies that compared schizoaffective disorder with schizophrenia
or mood disorders. J Affect Disord. 106:209–217. 2008.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Rey Souto D, Pinzón Espinosa J, Vieta E
and Benabarre Hernández A: Clozapine in patients with
schizoaffective disorder: A systematic review. Rev Psiquiatr Salud
Ment (Engl Ed). 14:148–156. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Correll CU and Howes OD:
Treatment-resistant schizophrenia: Definitions, predictors, and
therapy options. J Clin Psychiatry. 82(MY20096AH1C)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chopra PK, Couper JW and Herrman H: The
assessment of patients with long-term psychotic disorders:
Application of the WHO Disability Assessment Schedule II. Aust N Z
J Psychiatry. 38:753–759. 2004.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Holmberg C, Gremyr A, Torgerson J and
Mehlig K: Clinical validity of the 12-item. WHODAS-2.0 in a
naturalistic sample of outpatients with psychotic disorders. BMC
Psychiatry. 21(147)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Leucht S, Kane JM, Etschel E, Kissling W,
Hamann J and Engel RR: Linking the PANSS, BPRS, and CGI: Clinical
implications. Neuropsychopharmacology. 31:2318–2325.
2006.PubMed/NCBI View Article : Google Scholar
|
|
30
|
American Psychiatric Association:
Diagnostic and Statistical Manual of Mental Disorders. 4th Edition.
American Psychiatric Association, Washington, DC, 2000.
|
|
31
|
Startup M, Jackson MC and Bendix S: The
concurrent validity of the Global assessment of functioning (GAF).
Br J Clin Psychol. 41 (Pt 4):417–l422. 2002.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kirkpatrick B, Strauss GP, Nguyen L,
Fischer BA, Daniel DG, Cienfuegos A and Marder SR: The brief
negative symptom scale: Psychometric properties. Schizophr Bull.
37:300–305. 2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Østergaard SD, Lemming OM, Mors O, Correll
CU and Bech P: PANSS-6: A brief rating scale for the measurement of
severity in schizophrenia. Acta Psychiatr Scand. 133:436–444.
2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Østergaard SD, Foldager L, Mors O, Bech P
and Correll CU: The validity and sensitivity of PANSS-6 in the
clinical antipsychotic trials of intervention effectiveness (CATIE)
study. Schizophr Bull. 44:453–462. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Nielsen CM, Kølbæk P, Dines D, Pedersen
ML, Danielsen AA, Holmgård C, Wissing S, Esbøl AM, Fuglsang NFB,
Nguyen TD, et al: Validation of ratings on the six-item positive
and negative syndrome scale obtained via the simplified negative
and positive symptoms interview among outpatients with
schizophrenia. J Psychopharmacol. 36:1208–1217. 2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Geers LM, Loonen AJM and Touw DJ:
Microsampling techniques suitable for therapeutic drug monitoring
of antipsychotics. J Clin Psychopharmacol. 44:302–310.
2024.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Geers LM, Cohen D, Wehkamp LM, van Hateren
K, Koster RA, Fedorenko OY, Semke AV, Bokhan N, Ivanova SA,
Kosterink JGW, et al: Dried blood spot analysis for therapeutic
drug monitoring of clozapine. J Clin Psychiatry. 78:e1211–e1218.
2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Geers LM, Cohen D, Wehkamp LM, van Wattum
HJ, Kosterink JGW, Loonen AJM and Touw DJ: Population
pharmacokinetic model and limited sampling strategy for clozapine
using plasma and dried blood spot samples. Ther Adv
Psychopharmacol. 12(20451253211065857)2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Siskind D, Orr S2, Sinha S, Yu O, Brijball
B, Warren N, MacCabe JH, Smart SE and Kisely S: Rates of
treatment-resistant schizophrenia from first-episode cohorts:
Systematic review and meta-analysis. Br J Psychiatry. 220:115–120.
2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Verdoux H, Quiles C, Bachmann CJ and
Siskind D: Prescriber and institutional barriers and facilitators
of clozapine use: A systematic review. Schizophr Res. 201:10–19.
2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Warnez S and Alessi-Severini S: Clozapine:
A review of clinical practice guidelines and prescribing trends.
BMC Psychiatry. 14(102)2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zalsman G, Hawton K, Wasserman D, van
Heeringen K, Arensman E, Sarchiapone M, Carli V, Höschl C, Barzilay
R, Balazs J, et al: Suicide prevention strategies revisited:
10-year systematic review. Lancet Psychiatry. 3:646–659.
2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Khokhar JY, Henricks AM, Sullivan EDK and
Green AI: Unique effects of clozapine: A pharmacological
perspective. Adv Pharmacol. 82:137–162. 2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Olfson M, Gerhard T, Crystal S and Stroup
TS: Clozapine for schizophrenia: State variation in evidence-based
practice. Psychiatr Serv. 67(152)2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Okhuijsen-Pfeifer C, Cohen D, Bogers JPAM,
de Vos CMH, Huijsman EAH, Kahn RS and Luykx JJ: Differences between
physicians' and nurse practitioners' viewpoints on reasons for
clozapine underprescription. Brain Behav. 9(e01318)2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Rubio JM and Kane JM: How and when to use
clozapine. Acta Psychiatr Scand. 141:178–189. 2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
De Fazio P, Gaetano R, Caroleo M,
Cerminara G, Maida F, Bruno A, Muscatello MR, Moreno MJ, Russo E
and Segura-García C: Rare and very rare adverse effects of
clozapine. Neuropsychiatr Dis Treat. 11:1995–2003. 2015.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Smith RC, Leucht S and Davis JM:
Maximizing response to first-line antipsychotics in schizophrenia:
A review focused on finding from meta-analysis. Psychopharmacology
(Berl). 236:545–559. 2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Kelly DL, McMahon RP, Liu F, Love RC,
Wehring HJ, Shim JC, Warren KR and Conley RR: Cardiovascular
disease mortality in patients with chronic schizophrenia treated
with clozapine: A retrospective cohort study. J Clin Psychiatry.
71:304–311. 2010.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Jönsson L, Simonsen J, Brain C, Kymes S
and Watson L: Identifying and characterizing treatment-resistant
schizophrenia in observational database studies. Int J Methods
Psychiatr Res. 28(e1778)2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Correll CU, Brevig T and Brain C:
Exploration of treatment-resistant schizophrenia subtypes based on
a survey of 204 US psychiatrists. Neuropsychiatr Dis Treat.
15:3461–3473. 2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Marinkovic D, Timotijevic I, Babinski T,
Totic S and Paunovic VR: The side-effects of clozapine: A four year
follow-up study. Prog Neuropsychopharmacol Biol Psychiatry.
18:537–544. 1994.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Henderson DC, Fan X, Copeland PM, Borba
CP, Daley TB, Nguyen DD, Zhang H, Hayden D, Freudenreich O, Cather
C, et al: A double-blind, placebo-controlled trial of sibutramine
for clozapine-associated weight gain. Acta PsychiatrScand.
115:101–105. 2007.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Heald A, Livingston M, Yung A and De Hert
MA: Prescribing in schizophrenia and psychosis: Increasing
polypharmacy over time. Hum Psychopharmacol. 32:2017.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Correll CU, Brevig T and Brain C: Patient
characteristics, burden and pharmacotherapy of treatment-resistant
schizophrenia: Results from a survey of 204 US psychiatrists. BMC
Psychiatry. 19(362)2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Martini F, Spangaro M, Buonocore M, Bechi
M, Cocchi F, Guglielmino C, Bianchi L, Sapienza J, Agostoni G,
Mastromatteo A, et al: Clozapine tolerability in treatment
resistant schizophrenia: Exploring the role of sex. Psychiatry Res.
297(113698)2021.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Moreno-Küstner B, Martín C and Pastor L:
Prevalence of psychotic disorders and its association with
methodological issues. A systematic review and meta-analyses. PLoS
One. 13(e0195687)2018.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Procyshyn RM, Vila-Rodriguez F, Honer WG
and Barr AM: Clozapine administered once versus twice daily: Does
it make a difference? Med Hypotheses. 82:225–228. 2014.PubMed/NCBI View Article : Google Scholar
|
|
59
|
McKibbin C, Patterson TL and Jeste DV:
Assessing disability in older patients with schizophrenia: Results
from the WHODAS-II. J NervMent Dis. 192:405–413. 2004.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Lu ML, Lane HY, Lin SK, Chen KP and Chang
WH: Adjunctive fluvoxamine inhibits clozapine-related weight gain
and metabolic disturbances. J Clin Psychiatry. 65:766–771.
2004.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Lau SL, Muir C, Assur Y, Beach R, Tran B,
Bartrop R, McLean M and Caetano D: Predicting weight gain in
patients treated with clozapine: The role of sex, body mass index,
and smoking. J Clin Psychopharmacol. 36:120–124. 2016.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Jessurun NT, Derijks HJ, van Marum J,
Jongkind A, Giraud LE, van Puijenbroek P and Grootens KP: Body
weight gain in clozapine-treated patients: Is norclozapine the
culprit? Br J Clin Pharmacol. 88:853–857. 2022.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Ertuğrul A and Uluğ B: The influence of
neurocognitive deficits and symptoms on disability in
schizophrenia. Acta PsychiatrScand. 105:196–201. 2002.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Grover S, Naskar C and Chakrabarti S:
Impact of clozapine on disability and course of illness in patients
with schizophrenia: A study from North India. Indian J Psychiatry.
63:588–592. 2021.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Kappel DB, Rees E, Fenner E, King A,
Jansen J, Helthuis M, Owen MJ, O'Donovan MC, Walters JTR and
Pardiñas AF: Rare variants in pharmacogenes influence clozapine
metabolism in individuals with schizophrenia. Eur
Neuropsychopharmacol. 80:47–54. 2024.PubMed/NCBI View Article : Google Scholar
|
